Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
← catalyst calendarNCT06890598 · readout ≤ 1,015 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
700estimated
Sites
370
Countries
Australia, Austria, Belgium +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-27 | actual | When the study began enrolling |
| Primary completion | May 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Olomorasib — also filed as LY3537982
- Drug: Pembrolizumab
- Drug: Durvalumab
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Disease-Free Survival (DFS) by Investigator Assessment
measured Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years).
Part B: Progression-Free Survival (PFS) by BICR
measured Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed